SERASERAHealthcare · Medical Devices

SERA Stock Forecast: Sera Prognostics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.81
−4.23% on the day

The median 12-month analyst price target for Sera Prognostics, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$72.0M
Ticker Nerd rank
39/ 100
Median analyst target
$5.00
Analysts covering
4
Revenue$30K+76.5% y/y
Operating income−$10.0M
Net income−$9.1M
Free cash flow−$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.0%
1M
−10.8%
YTD
−38.6%
1Y
−42.2%
From 52W high
−50.9%
From 52W low
+13.8%
$1.59
$3.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sera Prognostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
74
Accruals
73
Volatility
56
Momentum
42
Revisions
39
Issuance
30
Quality
23
Value
20

Growth (74): Sales and profits are climbing, and climbing faster than before.

Value (20): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26SERAHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$5.00
Low
$5.00
Median
$5.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 June 2026Craig-HallumInitiatesBuy$6.00
10 Aug 2023CitigroupMaintainsNeutral—
10 Nov 2022CitigroupMaintainsNeutral—
14 Sept 2022BerenbergInitiatesBuy—
29 Aug 2022OppenheimerMaintainsOutperform—
27 Apr 2022BerenbergInitiatesBuy—
30 Mar 2022CitigroupDowngradeNeutral—
19 Nov 2021OppenheimerInitiatesOutperform—
9 Aug 2021CitigroupInitiatesBuy—
9 Aug 2021Cowen & Co.InitiatesOutperform—
9 Aug 2021William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SERA.

Market Radar

This page is one stock. Monday covers all of them.

SERA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sera Prognostics, Inc. returned −42.2% against +6.9% for the S&P 500, dividends included.

SERA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26SERAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
749.8×

Cheaper than 1% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−66.7%

Higher than 2% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−49.7%

Higher than 22% of US stocks

Return on assets
−24.7%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sera Prognostics, Inc. has a market value of $72.0M and an enterprise value of $31.2M.

  • Revenue in the twelve months to 30 June 2026: $70K. The latest quarter grew 76.5% year on year.

  • Net income over the same four quarters: −$33.2M, a −47475.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.67.

  • Free cash flow in the twelve months to 30 June 2026: −$28.2M.

  • Shares outstanding: 39.4M.

  • Sera Prognostics, Inc. employs 71 people — $985.9 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SERA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SERASera Prognostics, Inc.$72.0M39
LUCDLucid Diagnostics, Inc.$75.7M36
OWLTOwlet, Inc.$85.0M27
HYPRHyperfine, Inc.$58.0M42
CATXPerspective Therapeutics, Inc.$91.0M11
LNSRLENSAR, Inc.$54.8M58
QTRXQuanterix Corp.$92.3M53

Take a look at SERA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sera Prognostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SERA

What is the SERA stock price forecast for 2026-2027?

The median 12-month analyst price target for Sera Prognostics, Inc. is $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SERA stock a buy right now?

Of the 4 analysts covering Sera Prognostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sera Prognostics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SERA?

As at 21 Nov 2026, Sera Prognostics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (74 of 100).

Will SERA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $5, and Ticker Nerd's factor model ranks Sera Prognostics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SERA stock forecast for 2030?

No analyst covering Sera Prognostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

How has SERA stock performed over the past year?

Sera Prognostics, Inc. returned -42.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sera Prognostics, Inc. do?

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care. The company develops and commercializes blood-based biomarker tests and predictive analytics designed to help physicians assess pregnancy-related risks, with its flagship PreTRM test used to estimate the risk of spontaneous preterm birth in singleton pregnancies.

Company

About Sera Prognostics, Inc.

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care. The company develops and commercializes blood-based biomarker tests and predictive analytics designed to help physicians assess pregnancy-related risks, with its flagship PreTRM test used to estimate the risk of spontaneous preterm birth in singleton pregnancies. Sera Prognostics applies proteomics and bioinformatics to identify clinically useful markers from blood samples, supporting earlier risk awareness in prenatal care. Its product and service portfolio centers on pregnancy biomarker discovery, test validation, and diagnostic reporting for healthcare providers in the United States. Headquartered in Salt Lake City, Utah, and founded in 2008, Sera Prognostics operates as a specialized medical diagnostics business serving the broader women’s health and precision medicine markets.

CEO Ms. Zhenya Lindgardt M.B.A. · 71 employees · United States · https://www.sera.com